Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. (NY: SNY )

43.41 USD UNCHANGED
Last Price Updated: 5:16 PM EST, Dec 31, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Sanofi-Aventis S.A.

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Should Investors Consider Buying These Top Health In March? 4 To Watch
Tags Market News
From StockMarket.com
Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?
It's a real possibility. 
Tags SNY JNJ Market News
From Motley Fool
News From The Vaccine World
Less than a year before the COVID-19 started its relentless march across the globe Novavax (NASDAQ: NVAX) was facing delisting from the ... 
Tags IAM Newswire General MRK
From Benzinga
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags TTOO MDXG ACOR
From Benzinga
Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review
TheFDA has accepted for reviewthe supplemental marketing application seeking approval for Dupixent (dupilumab). It is an ... 
Tags Benzinga Market News Health Care
From Benzinga
Is Moderna Stock A Buy After Crushing Quarterly, Guidance Expectations?
Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride. Is Moderna stock a buy now? 
From Investor's Business Daily
Merck To Offer Hand With JNJ COVID-19 Vaccine Production, Biden Administration Says: Report
U.S. President Joe Biden will announce thatMerck & Co(NYSE:MRK) will help manufacture its rivalJohnson & ... 
Tags SNY Contracts Biotech
From Benzinga
Magenta Is Ready to Paint Your Portfolio Green
This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients. 
Tags BEAM MGTA BLUE
From Motley Fool
Pandion Therapeutics Surges To Record High On Merck's $1.85 Billion Buyout
Pandion Therapeutics stock blasted to a record high Thursday on Merck's plan to buy the IPO stock for $1.85 billion. Pandion just recently wrapped its initial public offering in July. 
From Investor's Business Daily
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11
Health Canada has approvedSanofi’s SA(NASDAQ:SNY) andRegeneron Pharmaceuticals ... 
Tags News REGN General
From Benzinga
FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer
The FDA approved expanded use ofRegeneron Pharmaceuticals Inc(NASDAQ:REGN) andSanofi’s ... 
Tags Market News Benzinga Biotech
From Benzinga
FDA Says Conduct Smaller Trials To Test Vaccine Efficacy Against COVID Variants
Amid concerning virus variants, the FDA said it would quickly analyze any vaccine booster shots against COVID-19 variants. The ... 
Tags BNTX Market News AZN
From Benzinga
Global Exception
Markets fell sharply over concern about high bond yields and potential inflation. 
Tags Stocks / Equities Market News
From Blogs - TalkMarkets
3 Green Flags for Novavax Investors, and 1 Red Flag
Since January 2020, Novavax has become 65-bagger. Is it still a buy? 
Tags Market News NVAX PFE
From Motley Fool
Bristol-Myers, Sanofi Fined $834M In Hawaii Over Plavix: Bloomberg
Bristol-Myers Squibb Co(NYSE:BMY) andSanofi SA(NASDAQ:SNY) wereordered to paythe state of ... 
Tags Legal Benzinga News
From Benzinga
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Biotech stocks advanced in the week ended Feb. 12, thanks to market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts, and a slew of... 
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap ... 
Tags OPK RPRX EXAS
From Benzinga
Amicus Stock Plunges After Rare-Disease Drug Misses In Key Study
Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday. 
From Investor's Business Daily
What Is Vaxart Worth Now?
The company can still produce returns without a COVID vaccine. 
Tags SNY JNJ VXRT
From Motley Fool
Sanofi Offers Cash Buyout For Kiadis
Sanofi SA(NASDAQ:SNY) haslaunched a takeover offerforKiadis Pharma NV(OTC: KIADF) to represent an ... 
Tags Biotech News KIADF
From Benzinga
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags KRTX IBB MREO
From Benzinga
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Sanofi SA(NASDAQ:SNY) andRegeneron Pharmaceuticals Inc's(NASDAQ:REGN) immunotherapy Libtayo ... 
Tags News Biotech FDA
From Benzinga
A Look Into Sanofi's Price Over Earnings
Looking into the current session, Sanofi Inc. (NASDAQ:SNY) shares are trading at $48.58, after a 0.77% increase. ... 
Tags BZI/PE Market News Earnings
From Benzinga
A Look Into Sanofi's Debt
Over the past three months, shares of Sanofi (NASDAQ:SNY) decreased by 4.51%. Before we understand the importance of debt, let ... 
Tags Markets Benzinga Intraday Update
From Benzinga
Should You Buy Lexicon Pharmaceuticals Stock?
Your portfolio could benefit from its group of soon-to-be-commercialized drugs. 
Tags Market News LXRX SNY
From Motley Fool
Sanofi (SNY) Q4 2020 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2020. 
Tags SNY Market News
From Motley Fool
What's Behind Regeneron's Stellar Q4 Update
The big biotech was firing on all cylinders, and getting strong growth out of its top-selling products. 
Tags SNY REGN Market News
From Motley Fool
Regeneron's Q4 Double-Digit Top and Bottom-Line Growth Propelled By Higher Sales From Eylea And Dupixent
Regeneron Pharmaceuticals Inc(NASDAQ:REGN)reported fourth-quarter earningsof $9.53 per share, which beat the ... 
Tags Market News Benzinga Guidance
From Benzinga
Sanofi: Q4 Earnings Insights
Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results. Quarterly ... 
Tags News SNY Market News
From Benzinga
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags PRTK JNJ IBB
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.